331 related articles for article (PubMed ID: 21964029)
1. NKT TCR recognition of CD1d-α-C-galactosylceramide.
Patel O; Cameron G; Pellicci DG; Liu Z; Byun HS; Beddoe T; McCluskey J; Franck RW; Castaño AR; Harrak Y; Llebaria A; Bittman R; Porcelli SA; Godfrey DI; Rossjohn J
J Immunol; 2011 Nov; 187(9):4705-13. PubMed ID: 21964029
[TBL] [Abstract][Full Text] [Related]
2. Human and mouse type I natural killer T cell antigen receptors exhibit different fine specificities for CD1d-antigen complex.
Wun KS; Ross F; Patel O; Besra GS; Porcelli SA; Richardson SK; Keshipeddy S; Howell AR; Godfrey DI; Rossjohn J
J Biol Chem; 2012 Nov; 287(46):39139-48. PubMed ID: 22995911
[TBL] [Abstract][Full Text] [Related]
3. Atypical natural killer T-cell receptor recognition of CD1d-lipid antigens.
Le Nours J; Praveena T; Pellicci DG; Gherardin NA; Ross FJ; Lim RT; Besra GS; Keshipeddy S; Richardson SK; Howell AR; Gras S; Godfrey DI; Rossjohn J; Uldrich AP
Nat Commun; 2016 Feb; 7():10570. PubMed ID: 26875526
[TBL] [Abstract][Full Text] [Related]
4. Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors.
Pellicci DG; Patel O; Kjer-Nielsen L; Pang SS; Sullivan LC; Kyparissoudis K; Brooks AG; Reid HH; Gras S; Lucet IS; Koh R; Smyth MJ; Mallevaey T; Matsuda JL; Gapin L; McCluskey J; Godfrey DI; Rossjohn J
Immunity; 2009 Jul; 31(1):47-59. PubMed ID: 19592275
[TBL] [Abstract][Full Text] [Related]
5. Defining a novel subset of CD1d-dependent type II natural killer T cells using natural killer cell-associated markers.
Singh AK; Rhost S; Löfbom L; Cardell SL
Scand J Immunol; 2019 Sep; 90(3):e12794. PubMed ID: 31141185
[TBL] [Abstract][Full Text] [Related]
6. The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR.
Pyz E; Naidenko O; Miyake S; Yamamura T; Berberich I; Cardell S; Kronenberg M; Herrmann T
J Immunol; 2006 Jun; 176(12):7447-55. PubMed ID: 16751390
[TBL] [Abstract][Full Text] [Related]
7. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
[TBL] [Abstract][Full Text] [Related]
8. Structural evaluation of potent NKT cell agonists: implications for design of novel stimulatory ligands.
Schiefner A; Fujio M; Wu D; Wong CH; Wilson IA
J Mol Biol; 2009 Nov; 394(1):71-82. PubMed ID: 19732779
[TBL] [Abstract][Full Text] [Related]
9. The V alpha 14 NKT cell TCR exhibits high-affinity binding to a glycolipid/CD1d complex.
Sidobre S; Naidenko OV; Sim BC; Gascoigne NR; Garcia KC; Kronenberg M
J Immunol; 2002 Aug; 169(3):1340-8. PubMed ID: 12133957
[TBL] [Abstract][Full Text] [Related]
10. Recognition of β-linked self glycolipids mediated by natural killer T cell antigen receptors.
Pellicci DG; Clarke AJ; Patel O; Mallevaey T; Beddoe T; Le Nours J; Uldrich AP; McCluskey J; Besra GS; Porcelli SA; Gapin L; Godfrey DI; Rossjohn J
Nat Immunol; 2011 Jul; 12(9):827-33. PubMed ID: 21804559
[TBL] [Abstract][Full Text] [Related]
11. Human invariant V alpha 24-J alpha Q TCR supports the development of CD1d-dependent NK1.1+ and NK1.1- T cells in transgenic mice.
Capone M; Cantarella D; Schümann J; Naidenko OV; Garavaglia C; Beermann F; Kronenberg M; Dellabona P; MacDonald HR; Casorati G
J Immunol; 2003 Mar; 170(5):2390-8. PubMed ID: 12594262
[TBL] [Abstract][Full Text] [Related]
12. Distinct CD1d docking strategies exhibited by diverse Type II NKT cell receptors.
Almeida CF; Sundararaj S; Le Nours J; Praveena T; Cao B; Burugupalli S; Smith DGM; Patel O; Brigl M; Pellicci DG; Williams SJ; Uldrich AP; Godfrey DI; Rossjohn J
Nat Commun; 2019 Nov; 10(1):5242. PubMed ID: 31748533
[TBL] [Abstract][Full Text] [Related]
13. Vβ2 natural killer T cell antigen receptor-mediated recognition of CD1d-glycolipid antigen.
Patel O; Pellicci DG; Uldrich AP; Sullivan LC; Bhati M; McKnight M; Richardson SK; Howell AR; Mallevaey T; Zhang J; Bedel R; Besra GS; Brooks AG; Kjer-Nielsen L; McCluskey J; Porcelli SA; Gapin L; Rossjohn J; Godfrey DI
Proc Natl Acad Sci U S A; 2011 Nov; 108(47):19007-12. PubMed ID: 22065767
[TBL] [Abstract][Full Text] [Related]
14. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
Hung JT; Huang JR; Yu AL
J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
[TBL] [Abstract][Full Text] [Related]
15. Cutting edge: influence of the TCR V beta domain on the avidity of CD1d:alpha-galactosylceramide binding by invariant V alpha 14 NKT cells.
Schümann J; Voyle RB; Wei BY; MacDonald HR
J Immunol; 2003 Jun; 170(12):5815-9. PubMed ID: 12794105
[TBL] [Abstract][Full Text] [Related]
16. CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens.
Hayworth JL; Mazzuca DM; Maleki Vareki S; Welch I; McCormick JK; Haeryfar SM
Immunol Cell Biol; 2012 Aug; 90(7):699-709. PubMed ID: 22041925
[TBL] [Abstract][Full Text] [Related]
17. Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy.
Wu TN; Lin KH; Chang YJ; Huang JR; Cheng JY; Yu AL; Wong CH
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17275-80. PubMed ID: 21987790
[TBL] [Abstract][Full Text] [Related]
18. A semi-invariant Vα10+ T cell antigen receptor defines a population of natural killer T cells with distinct glycolipid antigen-recognition properties.
Uldrich AP; Patel O; Cameron G; Pellicci DG; Day EB; Sullivan LC; Kyparissoudis K; Kjer-Nielsen L; Vivian JP; Cao B; Brooks AG; Williams SJ; Illarionov P; Besra GS; Turner SJ; Porcelli SA; McCluskey J; Smyth MJ; Rossjohn J; Godfrey DI
Nat Immunol; 2011 Jun; 12(7):616-23. PubMed ID: 21666690
[TBL] [Abstract][Full Text] [Related]
19. A minimal binding footprint on CD1d-glycolipid is a basis for selection of the unique human NKT TCR.
Wun KS; Borg NA; Kjer-Nielsen L; Beddoe T; Koh R; Richardson SK; Thakur M; Howell AR; Scott-Browne JP; Gapin L; Godfrey DI; McCluskey J; Rossjohn J
J Exp Med; 2008 Apr; 205(4):939-49. PubMed ID: 18378792
[TBL] [Abstract][Full Text] [Related]
20. In contrast to other species, α-Galactosylceramide (α-GalCer) is not an immunostimulatory NKT cell agonist in horses.
Dossa RG; Alperin DC; Garzon D; Mealey RH; Brown WC; Jervis PJ; Besra GS; Cox LR; Hines SA
Dev Comp Immunol; 2015 Mar; 49(1):49-58. PubMed ID: 25445911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
